Cost–Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn’s Disease

Pharmacoeconomics

Aug 26

Written by Matthijs Versteegh

CrohnCost-utility analysis

Matthijs Versteegh

Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study

Comparative efficacy of all available pharmaceutical therapies for moderate to severe Crohn’s disease: a systematic review and network meta-analysis